𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A novel and simple type of liposome carrier for recombinant interleukin-2

✍ Scribed by Eri Kanaoka; Kouji Takahashi; Takayoshi Yoshikawa; Hiroaki Jizomoto; Yoshitaka Nishihara; Koichiro Hirano

Book ID
111768646
Publisher
Pharmaceutical Press
Year
2001
Tongue
English
Weight
147 KB
Volume
53
Category
Article
ISSN
2042-7158

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Injectable magnetic liposomes as a novel
Injectable magnetic liposomes as a novel carrier of recombinant human BMP-2 for bone formation in a rat bone-defect model
✍ Matsuo, Toshihiro ;Sugita, Takashi ;Kubo, Tadahiko ;Yasunaga, Yuji ;Ochi, Mitsuo πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 337 KB

## Abstract Small‐sized magnetic liposomes with incorporated recombinant human bone morphogenetic protein‐2 (rhBMP‐2) were prepared, and the efficiency for bone formation after topical injection was evaluated in a rat bone‐defect model. A critical‐sized segmental bone defect was created in the mid‐

Pilot study of recombinant human interle
Pilot study of recombinant human interleukin 2 for chronic type B hepatitis
✍ Shinichi Kakumu; Akihiko Fuji; Kentaro Yoshioka; Hirofumi Tahara; Yoshiyuki Ohta πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 541 KB

Recombinant human interleukin 2 was administered to 10 patients with chronic type B hepatitis as a part of a pilot study to evaluate its antiviral activity. Patients received 1 to 3 x 10' units per day of interleukin 2 for 21 to 28 days, and all completed the treatment schedule. During therapy, seru

A pilot study of recombinant interleukin
A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C
✍ M Pardo; I Castillo; H Oliva; A Fernandez-Flores; R Barcena; M A de Peuter; V Ca πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 178 KB πŸ‘ 1 views

The optimal and safer interleukin-2 (IL-2) dose for treatment of chronic hepatitis C virus (HCV) infection has been studied in 33 HCV-RNA positive patients with chronic hepatitis C. Patients were randomly allocated to receive 5 days per week during 12 weeks IL-2 doses of: 0.9 MIU (n = 10), 1.8 MIU (